Arya Sciences Acquisition Corp II
Arya Sciences Acquisition Corp II is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Arya Sciences Acquisition Corp II.
Arya Sciences Acquisition Corp II is a company.
Key people at Arya Sciences Acquisition Corp II.
Key people at Arya Sciences Acquisition Corp II.
Arya Sciences Acquisition Corp II (Arya II) is a special purpose acquisition company (SPAC), or blank-check company, formed to raise capital via an IPO and merge with a target in biotechnology, life sciences, or healthcare technology.[2][3][6] Sponsored by affiliates of Perceptive Advisors and RA Capital Management, it targeted high-growth firms with novel drug candidates or platform technologies, particularly those advancing precision medicine.[1][2][4] Incorporated in early 2020 (initially Cayman Islands, later redomiciled to Delaware), it completed its $130-150 million IPO in June 2020 at $10 per unit under ticker ARYBU on Nasdaq (later OTC).[6][7]
Arya II merged with Cerevel Therapeutics in October 2020, creating Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) with ~$1.3 billion market cap and $445 million in net proceeds from PIPE investors like Perceptive, RA Capital, and others.[1][4][7] Post-merger, Arya II ceased independent operations, delivering public market access to Cerevel's neuroscience pipeline targeting schizophrenia, epilepsy, Parkinson's, and substance use disorders.[1]
Arya II was incorporated in February 2020 (per some records; IPO filings note 2020 founding) as a Cayman Islands exempted company, sponsored by ARYA Sciences LLC (affiliate of RA Capital Management) and Perceptive Advisors.[2][6][8] Key figures included CEO Adam Stone and a management team from RA Capital's healthcare investment group, leveraging expertise in biotech deal sourcing and execution.[2][7] The SPAC went public on June 5, 2020, raising ~$149.5 million fully in trust, underwritten by Jefferies and Goldman Sachs, with a 24-month tenor to find a target.[6][7]
Just over a month later, on July 30, 2020, it announced a business combination with Cerevel Therapeutics, a clinical-stage biotech unlocking neurocircuitry-based treatments.[1][7] Shareholder approval came October 26, 2020, closing October 27—expediting Cerevel's public debut amid 2020's SPAC boom in life sciences.[7]
Arya II rode the 2020 SPAC surge in biotech, fueled by low rates, retail investor enthusiasm, and demand for public biotech exposure amid COVID-accelerated innovation.[1][7] Timing was ideal: precision medicine and neuroscience were exploding, with neurocircuitry approaches addressing unmet needs in brain disorders.[1] Market forces like PIPE commitments from institutional heavyweights de-risked deals, influencing the ecosystem by fast-tracking ~20 clinical assets to public funding without traditional IPO hurdles.[1][4] It exemplified how SPACs democratized access for life sciences startups, boosting M&A in healthcare tech.
Arya II successfully exited via Cerevel merger, transitioning from blank-check to catalyst for neuroscience innovation—no longer active as a SPAC.[7] Cerevel (post-merger) advanced its pipeline, though later acquired by AbbVie in 2024 for $8.7 billion, underscoring the model's long-term impact.[1] Future SPAC iterations may face regulatory scrutiny and market cooldown, but Arya II's blueprint—specialized focus, strong networks—will shape selective biotech de-SPACs amid AI-driven drug discovery trends. This deal humanized high-stakes life sciences investing, proving SPACs' power to unlock brain science breakthroughs.[1][2]
